Can you summarize the differences in benzodiazepine withdrawal severity, onset, and duration for the various benzodiazepine medications?

Comment by InpharmD Researcher

There is a paucity of data on differences in withdrawal between benzodiazepine agents. Generally, benzodiazepine withdrawal can start within 10-12 hours of discontinuation (especially with shorter-acting agents); however, longer-acting benzodiazepines may take days before withdrawal phenomena appear. The withdrawal symptoms typically peak to acute withdrawal 2 weeks after discontinuing the benzodiazepine; higher doses and length of treatment are associated with more severe withdrawal symptoms. A third phase of benzodiazepine withdrawal may be a return of anxiety, which is known to persist until treated. Study findings indicated higher rates of withdrawal symptoms (including anxiety, insomnia, tremulousness, and irritability) with short-acting benzodiazepines with abrupt discontinuation, but no observable differences in severity of withdrawal symptoms between short-acting and long-acting benzodiazepines when reduced with a gradual taper.
Background

According to the American Addiction Centers, benzodiazepine withdrawal symptoms typically start within 24 hours of treatment and can last from a few days to several months, depending on the length of abuse and strength of the benzodiazepine(s) used. The occurrence of withdrawal is dependent on the agent’s half-life and the amount of time it takes for the drug to leave the bloodstream. For shorter-acting benzodiazepines (e.g., alprazolam), withdrawal may start within 10 to 12 hours of stopping the medication, whereas with longer-acting benzodiazepines (e.g., diazepam), it may take a few days for symptoms to appear. In general, the early withdrawal phase usually starts within a few hours to a few days of stopping the medication and may last several days. Around 2 weeks after stopping a benzodiazepine, acute withdrawal may begin, which constitutes the bulk of withdrawal symptoms. Risk factors for increased benzodiazepine withdrawal duration and intensity include the length of time taking benzodiazepines, the dose of benzodiazepines taken, other medications being taken or abused, the method of administering benzodiazepines, and underlying mental health issues. [1]

A 2008 review discussing the risk of withdrawal upon discontinuation of benzodiazepines stated certain risk factors that may predict the occurrence or increased risk of withdrawal severity, such as higher benzodiazepine dose, longer duration of benzodiazepine use, and immediate cessation or rapid tapering of the benzodiazepine dose. Data reporting benzodiazepine withdrawal remain conflicting. Some studies suggest that benzodiazepine half-life does not influence withdrawal symptoms, whereas others indicate benzodiazepines with a short half-life are associated with a faster onset of withdrawal symptoms or more severe withdrawal symptoms when therapy is stopped abruptly compared with long half-life benzodiazepines. A specific incidence of withdrawal seizures or delirium tremens associated with specific benzodiazepines was not reported within the review. [2]

Another review from 2004 suggests that the risk of withdrawal symptoms and especially seizures is greater with benzodiazepines with short and intermediate half-lives. With the gradual taper, however, withdrawal seizures are rare and generally occur in patients taking a high dose for longer than 4 months. Patients with a history of seizures are also more likely to be at risk for seizures. Concomitant use of drugs that may lower the seizure threshold can further present a risk. In general, short- and intermediate-half-life compounds carry greater risks for a rebound, withdrawal reactions, and dependence than long-acting agents. Clonazepam and diazepam, benzodiazepines with longer half-lives, have been found to result in fewer rebound and withdrawal symptoms compared to alprazolam. [3]

A 1994 review describing the characterization of benzodiazepine withdrawal syndrome also states that short-lived rebound symptoms (e.g., anxiety, insomnia) onset within 1-4 days of discontinuation, depending on the half-life of the benzodiazepine. The second part of benzodiazepine withdrawal, the full-blown withdrawal syndrome, lasts about 10-14 days. A third part of the withdrawal is a return of anxiety symptoms, which persist until it is treated. Withdrawal from benzodiazepines appears to be more severe when high doses or short-acting agents are used. [4]

A 1993 meta-analysis comprehensively evaluated the dependence potential and withdrawal profiles of benzodiazepines categorized by their half-life and potency. Data were systematically aggregated from multiple randomized controlled trials and observational studies involving a total of 1,302 subjects exposed to various benzodiazepines. The analysis stratified benzodiazepines into short- versus long-acting agents as well as high- versus low-potency classifications to assess differential impacts on the development of physical dependence, withdrawal severity, and rebound anxiety phenomena. Results demonstrated a statistically significant higher incidence of withdrawal-related anxiety symptoms and dropout rates among patients treated with short half-life benzodiazepines compared to their long half-life counterparts (p<0.004). High-potency, short half-life agents were particularly associated with more pronounced rebound anxiety and greater challenges during tapering protocols, as evidenced by elevated Hamilton Anxiety Scale scores and increased therapy discontinuations. Although heterogeneity among studies was noted, pooled effect sizes reinforced the notion that short-acting benzodiazepines carry a higher risk of physical dependence and withdrawal syndrome. Conversely, long half-life benzodiazepines showed lower withdrawal symptomatology and better patient retention during discontinuation phases, suggesting a pharmacokinetic advantage in reducing dependence potential. The meta-analysis underscores the clinical imperative to consider benzodiazepine pharmacodynamics when prescribing and managing long-term therapy to mitigate withdrawal morbidity. [5]

Background References: [1] American Addiction Centers. Benzo Withdrawal Symptoms, Timeline and Detox Treatment. Updated January 3, 2024. Accessed October 24, 2026. https://americanaddictioncenters.org/benzodiazepine/length-of-withdrawal
[2] Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2):69-86. doi:10.1111/j.1600-0404.2008.01004.x
[3] Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65 Suppl 5:7-12.
[4] Pétursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455-1459. doi:10.1111/j.1360-0443.1994.tb03743.x
[5] Hallfors DD, Saxe L. The dependence potential of short half-life benzodiazepines: a meta-analysis. Am J Public Health. 1993;83(9):1300-1304. doi:10.2105/ajph.83.9.1300
Literature Review

A search of the published medical literature revealed 4 studies investigating the researchable question:

Can you summarize the differences in benzodiazepine withdrawal severity, onset, and duration for the various benzodiazepine medications?

Level of evidence

C - Multiple studies with limitations or conflicting results  Read more→



Please see Tables 1-4 for your response.


 

A Double-Blind Comparison of the Effects of Gradual Withdrawal of Lorazepam, Diazepam and Bromazepam in Benzodiazepine Dependence

Design

Randomized, double-blind, controlled study

N= 68

Objective

To observe the withdrawal of benzodiazepines in patients who had taken prescribed benzo diazepines regularly for six months or more and had apparent withdrawal symptoms on reduction

Study Groups

Diazepam (n= 22)

Lorazepam (n= 23)

Bromazepam (n= 23)

Inclusion Criteria

Outpatients who were taking a prescribed benzodiazepine in regular dosage for six months or longer; were unable to reduce or stop their drug because of apparent withdrawal symptoms; were taking 2-16 mg of diazepam or equivalent; were taking the benzodiazepine for anxiety, insomnia, or related symptomatology; wished to stop taking benzodiazepines and were willing to reduce the dosages

Exclusion Criteria

Taking other psychotropic medications

Methods

Eligible patients were randomized to be switched from their normal benzodiazepine to either diazepam, lorazepam, or bromazepam at an equivalent dose. Each patient remained on this dosage until the end of the fourth week, after which the dosage was reduced by 25% every two weeks until complete withdrawal after 10 weeks.

If patients were unable to reduce their drugs at the appropriate time they were regarded as drop-outs for the purposes of the study.

Blood samples were taken to assess serum benzodiazepine levels to confirm complete withdrawal.

Duration

12 weeks (final assessment 2 weeks after stopping the benzodiazepines)

Outcome Measures

Study dropout or cessation failure; Comprehensive Psychopathological Rating Scale (CPRS) scores; Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) scores; Brief Scale for Anxiety (BAS) scores

Baseline Characteristics

 

Diazepam (n= 22)

Lorazepam (n= 23)

Bromazepam (n= 23)

Age, years

49.5 ± 12.6 42.1 ± 9.1 43.4 ± 12.0

Female

86% 74% 70%

Mean benzodiazepine treatment duration, months (range)

90 (6-300) 103 (7-300) 83 (6-204)

Results

Endpoint

Diazepam (n= 22)

Lorazepam (n= 23)

Bromazepam (n= 23)

Dropped out of the study

6 (27.3%) 10 (43.5%) 7 (30.4%)

Significant changes were seen in CPRS scores over the study duration in all patients (p< 0.01). Additionally, BWSQ scores also improved between weeks 4 and 12 in the groups (p< 0.01). There were no significant differences between the drug groups.

A trend showed lower BWSQ scores after switching from their current benzodiazepine to the study drug; however, an increase in symptoms at variable times during the withdrawal period was noted for all medications.

There were no significant changes in the BAS scores over time (p= 0.08). Likewise, there were no significant changes in pulse rate, systolic or diastolic blood pressure, or weight between weeks 4 and 12 or between the drug groups.

Subgroup analyses found that the dosage of benzodiazepine and diagnosis of a personality disorder were correlated with higher BWSQ scores.

Adverse Events

One patient (lorazepam group) committed suicide after 12 weeks of treatment

Dropouts occurred sporadically throughout the trial, with no consistent pattern noticed. Most patients who dropped out did so due to withdrawal symptoms (tactile hallucinations [feeling of internal raining], hot patches on the skin, numbness/weakness of the arms).

Study Author Conclusions

The results show that personality status and total dosage of benzodiazepine consumed are the main influences on the intensity of benzodiazepine withdrawal symptoms, and that lorazepam is also more likely to cause difficulties in withdrawal than either bromazepam or diazepam.

InpharmD Researcher Critique

This study did not report the scores evaluated or the starting benzodiazepine dose for participants. Additional limitations include the small sample size and high rate of drop-out.

 

Table 1 References:
[6] Murphy SM, Tyrer P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry. 1991;158:511-516. doi:10.1192/bjp.158.4.511
Long-term Therapeutic Use of Benzodiazepines II. Effects of Gradual Taper
Design

Comparative study

N= 63

Objective To compare the effect on withdrawal severity and acute outcome of a 25% per week taper of short half-life vs long half-life benzodiazepines in benzodiazepine-dependent patients
Study Groups

Long half-life (LHL) benzodiazepines (n= 25) 

Short half-life (SHL) benzodiazepines (n= 38)

Inclusion Criteria Age range 21 to 75 years; continuous, daily use of a benzodiazepine for a minimum of 12 months; stable maintenance dosage of benzodiazepine at study entry, in the range of 5 to 40 mg/day of diazepam or its equivalent
Exclusion Criteria Current diagnosis of schizophrenia or organic brain syndrome; history of seizure disorder; recent history of alcoholism or substance abuse; acute or unstable medical condition; pregnant or nursing
Methods Patients underwent a gradual taper of benzodiazepine dosage, consisting of a 25% reduction every week. Patients unable to tolerate the taper could slow the taper rate or receive treatment for emergent symptoms. Plasma levels were monitored, and assessments were conducted at baseline, during taper, and 5 weeks post-taper.
Duration 1984 to 1987
Outcome Measures

Primary: Withdrawal severity, acute outcome

Secondary: Predictors of withdrawal severity, benzodiazepine-free status at 5 weeks

Baseline Characteristics   All patients (n= 63)
Mean age, years ± standard deviation 46.7 ± 15.3
Female 34 (54%)

LHL benzodiazepines included diazepam (n= 20) and clorazepate (n= 5), with mean benzodiazepine doses of 14.6 mg/day and 15 mg/day, respectively (in diazepam dose equivalents).

SHL benzodiazepines included lorazepam (n= 28) and alprazolam (n= 10), with mean benzodiazepine doses of 22.9 mg/day and 35.5 mg/day, respectively (in diazepam dose equivalents).

Results   LHL Benzodiazepines (n= 25) SHL Benzodiazepines (n= 38)
Dropouts (restarted benzodiazepine therapy) 32% 42%

Physician Withdrawal Checklist

≥6 new items

≥50% increase from baseline

Increase in total score, ≥10%

 

 

52%

 

72%

 

 64%

 

 

58%

 

61%

 

61%

Physician global assessment (questionable to severe) 88% 88%
Adverse Events Withdrawal symptoms were common, including anxiety, insomnia, tremulousness, and irritability. Insomnia was particularly troublesome. Perceptual distortions and tinnitus were reported more frequently in LHL benzodiazepine-treated patients.
Study Author Conclusions The results of the current study confirm observations by
others that in long-term benzodiazepine users a withdrawal syndrome can be expected, even when low-to-moderate therapeutic doses of benzodiazepines are gradually tapered at the rate of 25% or less per week. Gradual taper minimized withdrawal symptoms to the point that no statistically significant differences in outcome or in withdrawal severity were observed between SHL and LHL benzodiazepines. Although the withdrawal experience was judged by study physicians to be generally in the mild-to-moderate range of intensity, still 42% of SHL and 32% of LHL benzodiazepine-treated patients were unable to become or remain free of benzodiazepines.
Critique The study provided valuable insights into the withdrawal process and highlighted the role of personality factors. However, the study's retrospective nature and the lack of a control group may limit the generalizability of the findings. The study also did not explore the impact of different tapering schedules or alternative therapies on withdrawal outcomes.
Table 2 References:
[7] Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908-915. doi:10.1001/archpsyc.1990.01810220024003
Long-term Therapeutic Use of Benzodiazepines I. Effects of Abrupt Discontinuation
Design

Double-blind, placebo-controlled study

N= 57

Objective To compare the effect of abrupt discontinuation of therapeutic doses of short half-life (SHL) and long half-life (LHL) benzodiazepines in benzodiazepine-dependent patients
Study Groups

Placebo (n= 47)

Continued benzodiazepine use (n= 10)

Inclusion Criteria Age range 21 to 65 years; continuous, daily use of a benzodiazepine for a minimum of the past 12 months; stable maintenance dosage in the range of 5 to 40 mg/d of diazepam or its equivalent
Exclusion Criteria Current diagnosis of schizophrenia or organic brain syndrome; history of seizure disorder; recent history of alcoholism or other substance abuse; acute or unstable medical condition; pregnant or nursing
Methods

Patients underwent a 3-week stabilization period before double-blind assignment to placebo or continued benzodiazepine use. Daily psychiatric assessments and benzodiazepine plasma level determinations were obtained for the first week after abrupt discontinuation.

Patients in the placebo group were further stratified by use of either SHL or LHL benzodiazepines, with outcomes evaluated against the continue benzodiazepine patients (listed as control group).

Duration December 1982 to February 1986
Outcome Measures Withdrawal severity, Relapse on benzodiazepines within 1 week
Baseline Characteristics   All patients (n= 57)
Mean age, years ± standard deviation 44.5 ± 9.7
Female 28 (49%)

LHL benzodiazepines included diazepam (n= 16) and clorazepate (n= 10), with mean doses of 11.6 mg/day and 12.5 mg/day, respectively. 

SHL benzodiazepines included lorazepam (n= 14) and alprazolam (n= 7), with doses of 4 mg/day and 1.5 mg/ day, respectively.

Results   LHL Benzodiazepines (n= 26) SHL Benzodiazepines (n= 21) Control (n= 10) p-value
Dropouts (restarted benzodiazepine therapy) 27% 57% 0 0.1

Physician Withdrawal Checklist 

≥6 new items

≥50% increase from baseline

Increase in total score, ≥10

 

 

61%

 

58%

 

58%

 

 

67%

 

81%

 

90%

 

 

10%

 

0

 

0

 

 

Not significant (NS)

 

0.02

 

0.02

Physician global assessment (questionable to severe) 85% 100% 0 NS
Adverse Events Adrenergic symptoms were more severe in SHL benzodiazepine-treated patients. No seizures or serious sequelae were observed.
Study Author Conclusions Abrupt discontinuation of benzodiazepines results in a withdrawal syndrome, more severe for short half-life benzodiazepines. Withdrawal severity is influenced by benzodiazepine half-life, dosage, and patient factors such as personality and baseline psychopathology.
Critique The study's double-blind design and daily assessments provide robust data on withdrawal severity. However, the high attrition rate may underestimate withdrawal severity, and the sample may not be representative of all long-term benzodiazepine users due to selection bias towards those with previous taper failures.
Table 3 References:
[8] Rickels K. Long-term therapeutic use of benzodiazepines: i. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47(10):899. doi:10.1001/archpsyc.1990.01810220015002

 

Withdrawal Reaction After Long-Term Therapeutic Use of Benzodiazepines

Design

Double-blind, placebo-controlled trial

N= 40

Objective

To provide unequivocal evidence of a clinically important syndrome of benzodiazepine withdrawal after long-term therapeutic administration of various agents in that class

Study Groups

Placebo (n= 19)

Diazepam (n= 21)

Inclusion Criteria

Patients 18 to 59 years old; daily use of a benzodiazepine for ≥3 months, with a cumulative benzodiazepine exposure (the product of the average daily dose in milligrams and the total duration of use in days) >2,700 mg of diazepam (or the equivalent); either reported problems attributed to the use of a benzodiazepine (e.g., loss of memory or worry about the consequences of use) or an inability to stop taking the drug because of symptoms that occurred during attempts at discontinuation

Exclusion Criteria

Active medical and psychiatric conditions, abuse of multiple drugs within the preceding 6 months, use of a centrally active medication other than benzodiazepine within 30 days of the beginning of the study

Methods

Patients underwent a 2-week baseline period, continuing their prescribed benzodiazepine. Patients were then randomized to either diazepam or placebo, with the dose of diazepam tapered down over the course of an 8-week period. Patients underwent weekly behavioral therapy sessions alongside experimental treatment. Patients developed a goal reduction amount (1-5 mg per week) with their therapist to taper down treatment in ideally 5-6 weeks; average reduction for patients receiving diazepam was 3.5 mg per week.

Duration

Not disclosed

Outcome Measures

Withdrawal symptoms: number of symptoms and symptom severity

Time to supplementation

Baseline Characteristics

 

Placebo

(n= 19)

Diazepam

(n= 21)

Mean age, years ± standard deviation (SD)

41.8 ± 10.8 40.1 ± 13

Male

53% 48%

Mean daily dose of benzodiazepine (mg of diazepam or equivalent) ± SD

13.9 ± 8.1 16.2 ± 11.5

Median months of benzodiazepine use before study (range)

75 (20-240) 72 (9-198)

In the placebo group, eight patients were treated with short-acting benzodiazepines (lorazepam [n= 5]; oxazepam [n= 3]), and eleven were treated with long-acting benzodiazepines (diazepam [n= 10]; flurazepam [n= 1]).

Results

Endpoint

Placebo

(n= 19)

Diazepam

(n= 21)

p-value

Withdrawal symptoms, mean ± SD

Number of symptoms

Severity of symptoms

 

9.7 ± 5.6

8.5 ± 2.6

 

3.5 ± 2.8

3.7 ± 3.2

 

<0.0001

<0.0001

Patients refusing to continue taking the study drug

37% 5% <0.025

Median time to supplementation, days

7.51 28.7 <0.01

Among patients treated with placebo, patients previously treated with short-acting benzodiazepines demonstrated faster onset of symptoms compared to patients previously treated with long-acting benzodiazepines (0.75 ± 0.7 days vs 5.1 ± 4.1 days, respectively; p<0.0089) and earlier time to worst symptoms (1 ± 0.5 days vs 9.6 ± 5.1 days; p<0.002). No significant differences seen in the number or severity of symptoms between groups.

Adverse Events

Common Adverse Events: Fear, somatic complaints, difficulty concentrating, tension, tinnitus, involuntary movements, confusion, anxiety

Serious Adverse Events: Not reported

Percentage that Discontinued due to Adverse Events: N/A

Study Author Conclusions

Our data support the view that a gradual reduction in the dose of benzodiazepines is the preferred technique for achieving abstinence in outpatients. When pharmacologic withdrawal was abrupt, symptoms were more frequent and more severe than when a gradual tapering technique was used. The relative contributions of behavioral therapy, general supportive care, and pharmacologic variables were not distinguished in this experimental design. However, it can be said with confidence that there is little justification for abrupt withdrawal, especially in the absence of adequate supportive care.

InpharmD Researcher Critique

Study limited by small sample size but strengthened by double-blind and placebo-controlled design. Findings demonstrate higher rates of acute withdrawal symptoms in patients previously treated with short-term benzodiazepines when allocated to placebo group, but differences were comparable to those in patients previously treated with long-acting benzodiazepines at the end of a 4-week tapering period.



Table 4 References:
[9] Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315(14):854-859. doi:10.1056/NEJM198610023151403